Strides Pharma Science

Strides Pharma Science EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 10.41 %. In the previous year, EBIT CAGR (5 Year) was 10.41 % — a change of 0.00% (lower).

EBIT CAGR 5Y

10.41 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Strides Pharma Science is 2025 10.41 % . EBIT CAGR (5 Year) of Strides Pharma Science was 2024 10.41 % . It decreases by 0.00% lower compared to the previous year.

The Strides Pharma Science EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2018
10.41 INR
Jan 1, 2019
10.41 INR
Jan 1, 2020
10.41 INR
Jan 1, 2021
10.41 INR
Jan 1, 2022
10.41 INR
Jan 1, 2023
10.41 INR
Jan 1, 2024
10.41 INR
Jan 1, 2025
10.41 INR
The Strides Pharma Science EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %0.00%
10.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

EBIT CAGR (5 Year) of Strides Pharma Science is 10.41 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Strides Pharma Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Strides Pharma Science

All Key Metrics — Strides Pharma Science